NCT07063745 2026-03-17
MountainTAP-29
Bristol-Myers Squibb
Phase 2/3 Recruiting
Clinical Trials
5 trialsNCT04093167 2026-03-11
Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer
Canadian Cancer Trials Group
Phase 2/3 Recruiting
NCT07100080 2026-03-03
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT07213375 2026-01-07
DEXTER
Rigshospitalet, Denmark
Phase 2/3 Recruiting
NCT06478108 2024-06-27
Interventional Software for Multi-immunotherapy of Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
Phase 2/3 Recruiting